Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose pantoprazole + amoxicillin versus standard quadruple therapy for Helicobacter pylori eradication
IRCT20260120068623N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pantoprazole, amoxicillin, furazolidone and bismuth subsalicylate in Helicobacter pylori infection (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: H. pylori eradication / response to treatment. Started Jun 2026; status: completed.
02
Drugs
pantoprazoleamoxicillinfurazolidonebismuth subsalicylate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20260120068623N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260120068623N1.